hsa-mir-30c promotes the invasive phenotype of metastatic breast cancer cells by targeting NOV/CCN3 by Dobson, Jason R. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2014-08-02 
hsa-mir-30c promotes the invasive phenotype of metastatic 
breast cancer cells by targeting NOV/CCN3 
Jason R. Dobson 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Cancer Biology Commons, Cell Biology Commons, Genomics Commons, Neoplasms 
Commons, and the Oncology Commons 
Repository Citation 
Dobson JR, Taipaleenmaki H, Hu Y, Hong D, Van Wijnen AJ, Stein JL, Stein GS, Lian JB, Pratap J. (2014). 
hsa-mir-30c promotes the invasive phenotype of metastatic breast cancer cells by targeting NOV/CCN3. 
Open Access Articles. https://doi.org/10.1186/s12935-014-0073-0. Retrieved from 
https://escholarship.umassmed.edu/oapubs/2418 
Creative Commons License 
This work is licensed under a Creative Commons Attribution 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
PRIMARY RESEARCH Open Access
hsa-mir-30c promotes the invasive phenotype of
metastatic breast cancer cells by targeting NOV/
CCN3
Jason R Dobson1,2, Hanna Taipaleenmäki1,3, Yu-Jie Hu1, Deli Hong1,4, Andre J van Wijnen1,5, Janet L Stein1,4,
Gary S Stein1,4, Jane B Lian1,4* and Jitesh Pratap1,6
Abstract
Background: For treatment and prevention of metastatic disease, one of the premier challenges is the
identification of pathways and proteins to target for clinical intervention. Micro RNAs (miRNAs) are short,
non-coding RNAs, which regulate cellular activities by either mRNA degradation or translational inhibition.
Our studies focused on the invasive properties of hsa-mir30c based on its high expression in MDA-MB-231
metastatic cells and our bioinformatic analysis of the Cancer Genome Atlas that identified aberrant hsa-mir-30c to
be associated with poor survival.
Methods: Contributions of hsa-mir-30c to breast cancer cell invasion were examined by Matrigel invasion transwell assays
following modulation of hsa-mir-30c or hsa-mir-30c* levels in MDA-MB-231 cells. hsa-mir-30c in silico predicted targets
linked to cell invasion were screened for targeting by hsa-mir-30c in metastatic breast cancer cells by RT-qPCR. The
contribution to invasion by a target of hsa-mir-30c, Nephroblastoma overexpressed (NOV), was characterized by siRNA and
invasion assays. Significant effects were determined using Student’s T-tests with Welch’s correction for unequal variance.
Results: MCF-7 and MDA-MB-231 cells were used as models of poorly invasive and late-stage metastatic disease,
respectively. By modulating the levels of hsa-mir-30c in these cells, we observed concomitant changes in breast
cancer cell invasiveness. From predicted targets of hsa-mir-30c that were related to cellular migration and invasion,
NOV/CCN3 was identified as a novel target of hsa-mir-30c. Depleting NOV by siRNA caused a significant increase in the
invasiveness of MDA-MB-231 cells is a regulatory protein associated with the extracellular matrix.
Conclusions: NOV/CCN3 expression, which protects cells from invasion, is known in patient tumors to inversely
correlate with advanced breast cancer and metastasis. This study has identified a novel target of hsa-mir-30c, NOV,
which is an inhibitor of the invasiveness of metastatic breast cancer cells. Thus, hsa-mir-30c-mediated inhibition of NOV
levels promotes the invasive phenotype of MDA-MB-231 cells and significantly, the miR-30/NOV pathways is
independent of RUNX2, a known target of hsa-mir-30c that promotes osteolytic disease in metastatic breast cancer
cells. Our findings allow for mechanistic insight into the clinical observation of poor survival of patients with elevated
hsa-mir-30c levels, which can be considered for miRNA-based translational studies.
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Background
Breast cancer is the most commonly diagnosed disease
among women. Aggressive breast cancers have high
potential to become metastatic, a transition that makes
clinical intervention difficult. In recent years, many of
the molecular mechanisms that facilitate a more invasive
or metastatic state have been characterized [1-3]. It has
been observed that the transcriptome of primary breast
cancer cells with a predisposition for metastasis can be
distinguished from non-metastatic breast cancer cells
[4]. This indicates that steady-state mRNA levels are
altered in pre-metastatic tissue to promote metastasis.
Therefore, it is critical to define the events leading to
and maintaining a metastatic transcriptional landscape
of metastatic breast cancer cells.
Assessing a cell’s transcriptome using RNA-seq or
hybridization arrays provides measurement of the steady-
state levels of cellular mRNAs. Cellular mRNA levels are
controlled at multiple levels: transcriptional rate; mRNA
processing and export; mRNA stability; and translational
rate. miRNAs are small non-coding RNAs that post-
transcriptionally regulate mRNA levels, many of which are
critical for development [5]. Similar to mRNAs, the
steady-state levels of miRNAs are also altered in cancer-
ous tissues as compared to normal cells. Further, just as
for protein coding RNAs, many non-coding RNAs have
the capacity to function as tumor suppressors and onco-
genes (often referred to as onco-miRs) [6,7]. miRNAs are
also involved in cancer cell metastasis (metasta-miRs), and
regulate key physiological steps in the metastatic process
of many cancers, including breast [2,8-11]. Hence,
characterizing members of this class of non-coding
RNAs is important in our understanding of breast
cancer development and progression.
We queried publicly available data from TCGA Breast
Cancer project [12] for aberrant miRNAs, and observed
that hsa-mir-30c is elevated in expression level or copy
number in approximately 4% or breast cancer patients.
Importantly, these patients have significantly poorer
survival than patients with normal hsa-mir-30c, which
suggests that hsa-mir-30c may be a key factor in breast
cancer progression. Using a cell-based model, we ob-
served an association between cellular invasion and high
levels hsa-mir-30c, which led us to hypothesize that the
observed clinical mortality phenotype associated with
aberrant hsa-mir-30c was as a result of hsa-mir-30c
regulation of breast cancer cell invasion. To address this
hypothesis, we examined factors targeted by hsa-mir-30c
that regulate breast cancer cell invasion. We investigated
potential cross talk between a factor known to be tar-
geted by miR-30c, RUNX2 [13], which promotes metas-
tasis and osteolytic disease [14]. Further, because there are
still many unknown players promoting the metastatic
phenotype of advanced breast cancer, we addressed other
targets of hsa-mir-30c, first by in silico analyses for targets
linked to cellular invasion, then functional investigation of
these potential targets.
Our key findings demonstrated that highly metastatic
MDA-MB-231 breast cancer cells have robust levels of
hsa-mir-30c compared to non-metastatic MCF-7 cells;
and that hsa-mir-30c promotes breast cancer cellular in-
vasion through targeting of NOV/CCN3, which we char-
acterized as an inhibitor of invasion. We demonstrated
the specificity of this pathway by showing: a) that only
the canonical strand of hsa-mir-30c is detected and
responsible for the invasive phenotype; and b) that hsa-
mir-30c-NOV/CCN3-mediated invasiveness is completely
independent of hsa-mir-30c targeting of RUNX2. Import-
antly, our cell-based experimental observations allow for
mechanistic insight into the clinical observations of both
hsa-mir-30c and NOV/CCN3, which suggests that the
hsa-mir-30c-NOV pathway is an important target for
future translational studies.
Results
hsa-mir-30c promotes the invasiveness of MDA-MB-231
breast cancer cells
Numerous miRNAs have been implicated in tumorigen-
esis, driving tumor progression, or promoting metasta-
ses; however, there are still many miRNAs that have yet
to be characterized with respect to these oncogenic pro-
cesses. Using cBioPortal [15,16] to investigate the genom-
ics and transcriptomics of TCGA breast cancer patients
[12], we observed frequent amplifications in the genes
MIR30C1 and MIR30C2, which encode the same mature
miRNA, hsa-mir-30c, as well as many patients with signifi-
cant (absolute value of Z-score > =2.0) changes in the levels
of hsa-mir-30c (Figure 1A). Importantly, patients with
alterations in copy number or expression of hsa-mir-30c
have significantly poorer (log-rank P-value < 1.09e-03) sur-
vival than their wild-type counterparts (Figure 1B). Be-
cause many of the observed alteration of hsa-mir-30c in
patents were amplifications, increased expression levels,
or both we sought to use cell-based models to characterize
the functional impact of modulation of hsa-mir-30c.
In vitro, MCF-7 breast cancer cells have been observed
to be less invasive than MDA-MB-231 cells [17]. Using
Real Time qPCR, we observed statistically significantly
higher levels of endogenous hsa-mir-30c in the more
invasive breast cancer cell line MDA-MB-231 compared
to the MCF7 cell line (Figure 1C). This finding suggests
that increased expression of hsa-mir-30c is associated
with more invasive breast cancer cells. To address the
effect of hsa-mir-30c on the invasive potential of MDA-
MB-231 cells, MDA-MB-231 cells were transfected with
either hsa-mir-30c or anti-mir-30c for 48 h and loaded
the cells into the top of the transwell culture plates with
or without a layer of Matrigel. Conditioned osteoblast
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media was placed in the bottom well as a chemoattractant
for the cells to mimic a bone environment (Figure 1D).
Using this assay, we observed that more MDA-MB-231
cells transfected with hsa-mir-30c invaded through the
Matrigel as compared to control transfected MDA-MB-
231 cells, which indicates that hsa-mir-30c promotes the
invasiveness of MDA-MB-231 cells. When MDA-MB-231
cells were transfected with anti-mir-30c, we observed that
less cells had invaded through the Matrigel as compared
to control transfected MDA-MB-231 cells. Taken together,
we conclude that hsa-mir-30c expression levels are linked
with the invasive potential of MDA-MB-231 metastatic
breast cancer cells.
The canonical 5-prime end of hsa-mir-30c, not the “star”
or 3-prime end of hsa-mir-30c, promotes the invasiveness
of MDA-MB-231 cells
During normal miRNA biogenesis, the stem-loop struc-
ture that is termed the pre-miRNA is cleaved and only
one end of the longer pre-miRNA is integrated into the
Dicer complex [18]. In the case of hsa-mir-30c, the 5’-end
of the stem-loop is most commonly detected as the
mature form of the miRNA [19]. When the “star” strand
(or in the case of hsa-mir-30c the 3’-end of the stem-loop)
is incorporated into the Dicer complex, a unique set of
mRNAs is predicted to be targeted for translational
repression of mRNA degradation. The phenomenon of
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Figure 1 hsa-mir-30c promotes the invasiveness of MDA-MB-231 cells and regulates RUNX2 levels. (A) Oncoprint of breast cancer
samples that have altered copy number in MIR30C1 or MIR30C2, or significantly differentially expressed levels of the mature miRNA, hsa-mir-30c.
Differentially expressed samples are defined by having a Z score greater than 2.0 or less than −2.0. Z is calculated as the difference between the
expression value of hsa-mir-30c and the mean expression value of hsa-mir-30c in samples that are diploid for MIR30C1/MIR30C2 divided by the
standard deviation of the expression values for hsa-mir-30c in samples that are diploid for MIR30C1/MIR30C2. (B) Survival plot of patients with
copy number alterations in MIR30C1/MIR30C2 or levels of hsa-mir-30c (red) versus patients with diploid MIR30C1/MIR30C2 or normal levels of
hsa-mir-30c. Log-rank P-value < 1.09e-03. (C) Real Time qPCR detection of hsa-mir-30c in MCF-7 and MDA-MB-231 cells, normalized to U6
RNA. Mean and SEM (error bars) for two technical replicates of two biological replicates. * = Student’s t-test with Welch correction p-value < 0.05.
(D) Representative Matrigel invasion assay using MDA-MB-231 cells following 48 h of transient transfection with non-targeting miRNA (NT), hsa-mir-30c
(30c) or anti-hsa-mir-30c (A-30c); cells were stained with HEMA3.
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alternate utilization of the non-canonical part of the
pre-miRNA has been observed in leukemic cells [20];
therefore, we investigated the extent to which this kind of
transformation may be occurring in MDA-MB-231
metastatic breast cancer cells.
To determine whether the hsa-mir-30c-mediated effect
on the invasiveness of MDA-MB-231 cells was due to
the canonical miRNA strand, we transiently transfected
MDA-MB-231 cells with either hsa-mir-30c-5p (canon-
ical) or hsa-mir-30c-3p (star) an measured the invasive
properties of MDA-MB-231 cells using a Matrigel
transwell assay. Transfection of MDA-MB-231 cells with
hsa-mir-30c-3p resulted in a reduction of the number of
cells that migrated through the transwells in the absence
of Matrigel; however, transfection with hsa-mir-30c-3p
did not significantly affect the number of cells that
invaded through Matrigel (Figure 2A-C).
We examined endogenous expression of the canonical
and star miRNA products of hsa-mir-30c miRNA bio-
genesis in the breast cancer cell lines (Figure 2D). Using
primers specifically designed to detect either the 5’- or
3’-form of hsa-mir-30c, we observed that the ratio of the
endogenous levels of the 5’-form were several hundred
fold higher than the 3’-form in both MDA-MB-231 and
MCF-7 breast cancer cells and that the canonical form is
5 fold higher in the MDA-MB-231 compared to the
MCF-7 cells. These results indicate that the phenomenon
of “star”-strand miRNA activity of hsa-mir-30c does not
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Figure 2 The 5’-end of the hsa-mir-30c hairpin is the predominant mature miRNA detected in and promoting the invasiveness of
MDA-MB-231 cells. (A) Representative images from Matrigel invasion assay following 48 h of transient transfection of siRNA of cells stained with
HEMA3. (B) Percent of cells that migrated through the control inserts, defined by count of stained cells on the bottom of the inserts as a percent
of cells loaded into inserts. Mean and SEM (error bars) for four technical replicates each of two biological replicates. (C) Percent of cells that
invaded through the Matrigel inserts, normalized to the number of cells that migrated through the control inserts. Mean with SEM (error bars) for
four technical replicates each of two biological replicates. * = Wilcoxon Rank Sum p-value < 0.01. (A-C) NT = non-targeting miRNA, 30c = hsa-mir-30c,
and 30c* = hsa-mir-30c-3p. (D) qPCR detection of endogenous hsa-mir-30c (hsa-mir-30c-5p) and hsa-mir-30c* (hsa-mir-30c-3p) in MCF-7 and
MDA-MB-231 cells. Mean with SEM (error bars) for two technical replicates each of two biological replicates normalized to U6 snRNA using
the delta-Ct method. * = p-value from Student’s t-test with Welch correction comparing hsa-mir-30c (hsa-mir-30c-5p) and hsa-mir-30c*
(hsa-mir-30c-3p) in MDA-MB-231 cells < 0.05.
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make a major contribution to the invasiveness of MDA-
MB-231 cells. Instead, only the canonical 5’-strand of hsa-
mir-30c appears to be promoting the invasive phenotype
of MDA-MB-231 metastatic breast cancer cells.
Screening via ontological terms and qPCR reveals NOV to be
a target of hsa-mir-30c in MDA-MB-231 breast cancer cells
To identify potential targets of hsa-mir-30c participating
in the invasive phenotype associated with hsa-mir-30c
expression in MDA-MB-231 cells, we performed a
screen in three steps: 1) generated a list of potential
targets based on seed sequence targeting potential using
the top 300 human mRNA targets from www.microrna.
org [21]; 2) filtered the list based on known functions
and ontological terms for mRNAs that code for proteins
associated with invasion, adhesion, or migration, as well
as mRNAs that code for transcription factors [22,23]
(Table 1); 3) used qPCR to measure the relative mRNA
levels of potential targets in MDA-MB-231 cells that had
been transfected with either non-targeting miRNA or
hsa-mir-30c. Using this screening approach, we observed
that NOV mRNA was one of the two most down
Table 1 Genes chosen for qPCR screen
Predicted hsa-mir-30c targets from microRNA.org
Gene symbol mirSVR Score References into function or ontology terms
TWF1 −3.02 GO: Actin Binding
Regulates actin filament turnover [31]
Promotes cellular motility through actin
regulation [32]
DYNLT3 −3.02 GO: Cytoplasm, GO: Plasma Membrane
Cytoplasmic dynein light chain protein that interacts with spindle checkpoint protein BUB3 [33]
Functions as a nuclear matrix-associated transcription factor in a dynein-independent manner [34]
NEDD4 −2.47 Modulates p-Smad1 signaling in response to both BMP-2 and TGFβ1 [35]
Negatively regulates PTEN in an oncogenic fashion [36]
Involved in the deposition of extracellular collagen [37]
PTPN3 −2.55 Regulates EGF-mediated cell-cell contact [38]
Regulates focal adhesion [39]
Regulates Cadherin-mediated cell-cell contact [40]
Regulates neural crest cell adhesion and motility [41]
Controls hormone receptor signaling [42]
Cooperates with vitamin D to promote breast cancer cell growth [43]
ADAM22 −2.44 GO: Extracellular, GO: Metallopeptidase Activity
Metalloproteinase-like, disintegrin-like, cysteine-rich protein that is highly expressed in
brain tissue [44]
Promotes cell adhesion and spreading [45]
Cooperates with SRC-1 in endocrine resistance of breast cancer cells; expression of ADAM22
independently predicts poor survival in patients [46]
NOV −3.11 Regulates actin cytoskeletal reorganization [28]
Increases motility of chondrosarcoma cells [47]
Promotes mineralization of osteoblasts [48]
Transcriptionally activated by p53 [24]
Downregulated in advanced melanomas [26]
Downregulated in childhood adrenocortical tumors [25]
Significantly over-expressed in ER-positive breast cancer patients who relapsed after tamoxifen
treatment [49]
Expression is negatively correlated with metastasis and progression in breast cancer [50]
Promotes xenograph breast cancer bone-metastasis and osteolysis [27]
CELSR3 −4.03 GO: G-protein coupled receptor signaling pathway, GO: neuron migration, and GO: plasma membrane
Genes were chosen for qPCR screen based on: mirSVR score (www.microrna.org) [21], NCBI GeneRIF [22], and ontological terms [23]. TWF1 references: [31,32].
DYNLT3 references: [33,34]. NEDD4 references: [35-37]. PTPN3 references: [38-43]. ADAM22 references: [44-46]. NOV references: [24-28,47,48,50].
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regulated in silico-identified target upon transfection of
hsa-mir-30c (Figure 3A). We also examined several in
silico-predicted targets related to cancer at the protein
level and found these to be unaffected by the levels of
hsa-mir-30c (Additional file 1: Figure S1). We focused
on NOV, which is a member of the CCN family of
matricellular signaling proteins, and has context-specific
functions as an oncogene/tumor suppressor [24-28].
While CELSR3 had similar response trends to hsa-mir-
30c overexpression and is involved in cellular adhesion
[29], we did not focus on CELSR3 because the expres-
sion levels were very low in MDA-MB-231 cells (data
not shown) and CELSR3 was previously shown to not
affect invasion in metastatic melanoma cells [30]. In
parallel we also looked at in silico-predicted targets of
hsa-mir-30c that have known functions in cancer and
found that none of these predicted targets were affected
by overexpression of hsa-mir-30c (Additional file 1:
Figure S1). Using Western blotting to detect the levels
of NOV protein, we also observed NOV protein to be
reduced following transfection of MDA-MB-231 cells
with hsa-mir-30c (Figure 3B). The observation that
NOV mRNA was reduced upon transfection of hsa-
mir-30c was highly reproducible in multiple biological
replicates (Figure 3C), consistent with the reduction in
protein levels.
Comparing the sequence of hsa-mir-30c and the
sequence of the NOV 3’-UTR, mirSVR [52] predicted
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Figure 3 Predictive, ontological, and qPCR screen for hsa-mir-30c reveals NOV as a target of hsa-mir-30c. (A) The log2 of the fold change
in mean with SEM detection levels (hsa-mir-30c/non-targeting miRNA) is plotted for each set of primers for each transcript normalized to HPRT
using delta-delta Ct method [51]. (B) Representative Western blots for lysates extracted from MDA-MB-231 cells following 48 h of transient
transfection with either non-targeting miRNA (NT) or hsa-mir-30c (30c). Top blot: NOV, bottom blot: Lamin C. (C) qPCR for NOV levels for
two technical replicates each for three biological replicates following 48 h transient transfections of non-targeting miRNA (NT) or hsa-mir-30c (30c)
normalized to HPRT using delta-delta Ct method [51]. Mean with SEM. ** = p-value from Student’s t-test with Welch correction < 0.01. (D) Alignment of
hsa-mir-30c (top sequences) with the 3’-UTR of NOV (bottom sequences) with the 5’-positions within the NOV 3’-UTR being relative to the 5’-start of the
3’-UTR for each of the three predicted targeting sites. Target scores are provided by mirSVR. Uppercase letters linked with a “|” character indicates a perfect
match, while uppercase letters linked with a “:” character indicates a wobble pair.
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three potential binding sites for hsa-mir-30c (Figure 3D).
Among the mir-30 family members, hsa-mir-30c appears
to have the highest chance to target NOV as a unique
site is predicted for hsa-mir-30c that is not shared by
the other mir-30 family members (Additional file 2:
Figure S2). Based on ontological terms associated with
NOV, and the observed reduction of NOV protein and
mRNA levels in response to increased hsa-mir-30c
levels, we suggest that NOV is involved in the regula-
tion of MDA-MB-231 invasiveness.
hsa-mir-30c regulation of NOV and invasion is
independent of RUNX2
Numerous factors have been implicated in the progres-
sion of breast cancer metastasis, and among these
is RUNX2, a bone-lineage transcription factor that
promotes the invasive phenotype of MDA-MB-231 cells
[53-55]. Because mmu-mir-30c is known to target Runx2
[13], we addressed whether there is regulatory cross talk
between RUNX2, hsa-mir-30c, and NOV in breast cancer
cells. RUNX2 levels were modulated in MDA-MB-231 by
several approaches: overexpression, siRNA knockdown
and by examining a functionally-deficient mutant form of
Mus musculus Runx2 (R398A/Y428A), which inhibits the
invasiveness of MDA-MB-231 [54-56] (Figure 4). We
observed that constitutive overexpression of Runx2 or the
R398A/Y428A-mutant form of Runx2 in MDA-MB-231
cell lines (see Methods) did not alter either the protein
levels of NOV (Figure 4A) or the levels of hsa-mir-30c
(Figure 4B), which were measured by Western blot and
Real Time qPCR, respectively. Knockdown of RUNX2 via
siRNA has also been previously shown to inhibit the inva-
siveness of MDA-MB-231 cells [53]. To further investigate
whether RUNX2 can regulate the hsa-mir-30c/NOV
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pathway, endogenous RUNX2 levels in MDA-MB-231
cells were reduced via siRNA. We observed that NOV
protein levels were not affected by RUNX2 knockdown
(Figure 4C), and that hsa-mir-30c levels, while slightly
reduced, were not statistically significantly changed by
RUNX2 siRNA (Figure 4D). These results demonstrate
that the hsa-mir-30c/NOV-mediated regulation of the
invasiveness of MDA-MB-231 cells is occurring through a
RUNX2-independent pathway.
NOV inhibits the invasiveness of MDA-MB-231 cells
To determine the extent to which hsa-mir-30c targeting
and reduction of NOV was involved in the increased
invasion of MDA-MB-231 cells following transfection of
hsa-mir-30c, we transfected MDA-MB-231 cells with
NOV-specific siRNA to reduce NOV protein levels
without directly affecting other targets of hsa-mir-30c
(Figure 5A). We postulate if hsa-mir-30c-mediated down-
regulation of NOV levels is a key contributor to the inva-
siveness of MDA-MB-231 cells, we should therefore
observe that siRNA-mediated knockdown of NOV
results in an invasive phenotype similar to overexpres-
sion of hsa-mir-30c. The levels of NOV were significantly
reduced by the siRNA (Figure 5A), and using Matrigel
invasion assay, we observed an increase in the number
of MDA-MB-231 that invaded through the Matrigel
(Figure 5B-D). MDA-MB-231 cells lacking NOV were
significantly more invasive (Figure 5D), yet were less
migratory (Figure 5C). While it is often observed that
trends in invasion and migration are positively correlated,
NS siNOV
NOV
Lamin C
A NS siNOV
M
ig
ra
tio
n
In
va
si
on
B
100
60
20
NS siNOV NS siNOV
60
40
20
Pe
rc
en
t o
f M
ig
ra
tio
n
Pe
rc
en
t o
f I
nv
as
io
n
C D
Figure 5 NOV inhibits the invasiveness of MDA-MB-231 cells. (A) Representative Western blot for NOV (upper blot) and tubulin (lower blot)
48 h post-transfection with siRNA. Vertical dashed line indicates where image of gel was cut for figure. (B) Representative image of HEMA-3
stained cells, which migrated through either the control inserts (upper row) or Matrigel inserts (lower row) after 48 h of transfection with siRNA.
(C) Quantification of 4 technical replicates of 2 biological replicates measuring the percent of cells that migrated through the control inserts
(100 % being the number of cells loaded into the inserts). (D) Quantification of 4 technical replicates of 2 biological replicates measuring the
percent of cells that invaded through the Matrigel normalized by the number of cells migrated through the control inserts. (A-D) NS =Non-silencing
siRNA, siNOV =NOV siRNA. (C, D) Bars equal mean, error bars equal SEM. ** =Wilcoxon Rank Sum p-value < 0.01.
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we observed less migration coupled with increased inva-
sion in the absence of NOV. These results suggest that in
MDA-MB-231 cells, NOV has distinct regulatory roles for
the pathways governing invasion and migration. Taken to-
gether, our findings support the conclusion that the target-
ing of NOV by hsa-mir-30c is an important factor in the
invasive phenotype evidenced by the MDA-MB-231 cells
as illustrated in Figure 6.
Discussion
Here we identify a novel pathway by which hsa-mir-30c
promotes the invasiveness of the MDA-MB-231 cell line
through targeting of NOV. The specificity of NOV’s in-
volvement in the invasive phenotype observed by several
experimental approaches including the knockdown by
an siRNA targeting NOV, which resulted in significant
increases in the invasiveness of MDA-MB-231, consist-
ent with the high levels of hsa-mir-30c, and NOV cellular
protein levels in these cells. These results demonstrate a
novel pathway by which a miRNA (hsa-mir-30c) promotes
the invasive phenotype of metastatic breast cancer cells.
The large mir-30 family shares a conserved seed
sequence. However, our in silico research suggests that
seed sequence differences may give rise to selectivity in
targeting aggressive compared to modestly invading cells
among mir-30 members. It is appreciated from the
literature that the miR-30 family has numerous targets,
and others have been identified in breast [57-59] and
hsa-mir-30c
RUNX2 NOV/CCN3
Breast Cancer
Cell Invasion
hsa-mir-30c
targets RUNX2
RUNX2 transcriptionally
activates metastatic genes
hsa-mir-30c
targets NOV/CCN3
NOV/CCN3
inhibits invasion
Invasiveness of breast
cancer cells correlates 
with hsa-mir-30c levels
hsa-mir-30c is
aberrant in 4% of
breast cancer patients
Figure 6 Model of impact of hsa-mir-30c on breast cancer cell invasion. Left side: hsa-mir-30c targets and inhibits RUNX2 levels (data not
shown and [13]); RUNX2 expressed in metastatic breast cancer cells promotes breast cancer cell invasion [14]. Right side: hsa-mir-30c targets and
inhibits NOV/CCN3 levels (Figure 3); NOV/CCN3 inhibits breast cancer cell invasion (Figure 5). Thus the down regulation of NOV/CCN by miR30c
contributes to invasive properties. The hsa-mir-30c-RUNX2 pathway is independent of the hsa-mir-30c-NOV/CCN3 pathway (Figure 4). This model
of two factors RUNX2 and NOV, each with opposing roles in the invasiveness of metastatic breast cancer cells, are targets of a miR-30c regulatory
circuit that reflects the hsa-mir-30c is likely to have many targets that potentially contribute to different properties of breast cancer cells.
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other cancers [30,60-64]. For example, a recent study
showed that has-mir-30a marker targets the 3’-UTR of
Vimentin (VIM) which was observed to cause reductions
in both VIM protein levels and invasiveness of MDA-
MB-231 cells [63], and here we demonstrate that miR-
30c also promotes cellular invasion by targeting NOV. It
is also quite interesting that these mir-30 miRNAs ap-
pear on many chromosomes rather than co-regulated in
a cluster, and are involved in the regulation of a myriad
of pathways such as tumor suppression (p53) [63], apop-
tosis (BCL) [64], and epithelial to mesenchymal transi-
tion (VIM) [59]. Individual members of the mir-30
family have been implicated in both tumor suppression
and oncogenesis; it is therefore difficult to define the
family as a “tumor suppressive” or “oncogenic”. This am-
biguity makes studying the functions of the mir30 family
members on a case-by-case basis critical for understand-
ing the basis of post-transcriptional molecular mecha-
nisms of disease. The relative levels of the mir-30 family
members and their temporal expression may play a
critical role in disease progression.
Also, to be considered is the context in which our
experiments were conducted. We investigated the func-
tions of hsa-mir-30c in MCF-7, a less invasive breast
cancer cell line and the more invasive MDA-MB-231
cells, which is a cell model of advanced metastatic breast
cancer [65]. We find a positive in correlation in levels of
hsa-mir-30c and invasion properties in vitro assays and
high expression of hsa-mir-30c has been observed in
MDA-MB-231cells, as well as in other cellular models of
breast cancer. However detection of hsa-mir-30c did not
appear to be predictive of breast cancer subtypes [66].
Our cell-based observations are similar to observations
made in in vivo studies of miRNA expression patterns in
breast cancer patient samples in which hsa-mir-30c ex-
pression was not significantly associated with any clinical
or pathological features [12,67-70]. However, elevated
expression of hsa-mir-30c was observed to be signifi-
cantly associated with estrogen receptor (ER) positive
breast cancers that were beneficially responsive to tam-
oxifen treatment [58]. In a separate study, ER-positive
breast cancer patients who relapsed after tamoxifen
treatment had significantly increased levels of NOV [49],
which further underscores the inverse relationship be-
tween NOV and hsa-mir-30c in breast cancer, as well as
in our observations of low hsa-mir-30c in the ER positive
cell line (MCF-7) and higher levels in the MDA-MB-231
cells which are ER negative.. Thus, we have observed that
hsa-mir-30c was important for the invasive properties
which is discordant with the in vivo observations that
hsa-mir-30c expression was not positively associated with
metastatic disease, but rather, with positive outcome in re-
sponse to hormone therapy. We therefore suggest that the
cohort of potential mRNA targets available to hsa-mir-30c
in patients may be quite different from those in MDA-
MB-231 cells, which could explain the differences between
in vivo tumors with a heterogenous tumor cell population
and individual cell lines. The significance of our findings is
that there are likely to be tumor cells during progression
of breast cancer in vivo that could benefit from targeted
hsa-mir-30c or NOV therapy in reducing invasion and
later stage metastasis.
We have demonstrated that the functional conse-
quence of increased invasiveness of MDA-MB-231 cells
following the reduction of NOV through either hsa-mir-
30c or NOV-siRNA is directly sensitive to NOV levels.
NOV appears to play a context-sensitive role in onco-
genesis/tumor suppression [71]. In several cancers that
develop from mesenchymal tissues, NOV has been
shown to promote tumor growth and metastasis [72-74].
However, in the context of brain cancer, NOV appears
to inhibit disease progression [53,75-77], but in the
context of alveolar rhabdmyosarcoma NOV/CCN3 levels
are increased and contribute to survival of oppressive
behaviors of the cancerous cells promotes motility.
While there are conflicting observations of NOV func-
tions in breast cancer cell lines [28,49], NOV protein
levels in human tissue samples of breast cancer were
observed to be negatively correlated with late-stage and
metastatic disease [50]. These histological observations
suggest that in breast cancer, NOV functions to inhibit
disease progression.
Conclusions
We have demonstrated that hsa-mir-30c-mediated in-
hibition of NOV levels promotes the invasive phenotype
of MDA-MB-231 cells. We find that lower levels of the
canonical hsa-mir-30c are correlated with modest inva-
sion of MCF-7 compared to the aggressive invasion of
MDA-MD-231 cells, which express high levels of hsa-
mir-30c. The mechanism we have uncovered related to
hsa-mir-30c is that that the functional consequence of
increased invasiveness of MDA-MB-231 cells following
the targeting and reduction of NOV through either hsa-
mir-30c or NOV-siRNA and that the invasive properties
of the metastatic breast cancer cell line MDA-MB-231i
are directly sensitive to NOV levels. NOV/CCN3 expres-
sion in patients is known to inversely correlate with
advanced breast cancer and metastasis. Thus, a key
function of NOV is the inhibition of the invasiveness of
metastatic breast cancer cells.
Methods
Cell Properties
Cell lines
MCF-7 cells were grown in DMEM in media and MDA-
MD-231 cells in alpha MEM and maintained as previ-
ously described [53]. These cells have been maintained
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in our laboratory and used in seven publications since
2005. In 2012 the cells were revalidated by satellite phe-
notyping. These cell lines were grown and maintained as
previously described [53]. Constructs and stable cell lines
were generated as previously described [56]. MDA-MB-
231 cells which were lentivirus-transduced stable cell lines
to express either empty vector, wild-type Mus musculus
Runx2 a subnuclear-targeting-deficient mutant form of
Mus musculus Runx2 (R398A/Y428A), which inhibits the
invasiveness of MDA-MB-231 [54-56] were used in these
studies.
RNA isolation
RNA was isolated using Qiagen miRNAeasy Mini Kit
(217004) following the manufacturer’s recommended
protocol with optional in-column DNAse I digestion of
genomic DNA (Qiagen RNase-Free DNase Set 79254).
miRNA amplification and detection
Complimentary miRNA-specific cDNA was amplified
and detected using Applied Biosystems TaqMan Micro-
RNA Assays for hsa-mir-30c (#4427975) hsa-mir-30c-2*
(#4427975) and RNU6B (#4427975).
cDNA amplification and detection
cDNA was amplified from equal quantities of total cellular
RNA for each treatment or cell line. cDNA was amplified
using the Invitrogen SuperScript First-Strand Synthesis
System for RT-PCR (#11904-018) according to the manu-
facturer’s protocol. Reactions were volumetrically diluted,
and reaction products were used as templates for Real
Time qPCR using Bio-Rad iQ SYBR Green Supermix
(#170-8880).
cDNA qPCR primers
Real Time qPCR primers were designed using FoxPrimer
(www.foxprimer.org) and validated for efficiency by stand-
ard curve using cDNA amplified from untreated MDA-
MB-231 cells.
Protein isolation and Western blotting
Cells grown on tissue culture plates were placed directly
on ice, and washed twice with PBS supplemented with
Roche cOmplete, EDTA-free Protease Inhibitor Cocktail
(#11873580001) and 25 μM MG132 (Calbiochem (EMD
Millipore) CAS 133407-82-6). Cells were scraped into
screw-top microcentrifuge tubes, gently spun down to
pellet cells and excess PBS was aspirated and discarded.
Cells were snap-frozen in liquid nitrogen. Protein lysates
were prepared by the addition of RIPA buffer (50 mM
Tris pH 7.4, 150 mM NaCl, 2 mM EDTA, 1% v/v
NP-40, 0.1% w/v SDS, 1× Roche cOmplete, EDTA-free
Protease Inhibitor Cocktail and 25 μM MG132) and pla-
cing tubes on a 100 °C heat block for 10 min. Protein
lysates were quantified using Pierce BCA Protein Assay Kit
(#23225) according to manufacturer’s instructions. Fifty μg
protein per sample was loaded onto an SDS-PAGE gel.
SDS-PAGE was performed as described [53]. Briefly,
lysates were run through an 8.5% acrylamide gel, and
then transferred to a PVDF Transfer Membrane (Thermo
Scientific #88518).
Membranes were blocked with 5% (w/v) milk (BioRad
#170-6404XTU) in PBS and then subjected to immuno-
detection using the following primary antibodies and
dilution factors in 1% (w/v) milk in PBS: NOV (Santa
Cruz Biotechnology H-71 sc-50304 1:1000), Lamin A/
C (Santa Cruz Biotechnology N-18 sc-6215 1:5000), α-
Tubulin (Santa Cruz Biotechnology H-300 sc-5546
1:2000), RUNX2 (mouse hybridoma clone 8G5 1:1000)
[53], FOXG1 (Santa Cruz Biotechnology N-15 sc-1858),
SATB2 (Santa Cruz Biotechnology H-118 sc-98677),
SMAD2 (Santa Cruz Biotechnology S-20 sc-6200),
MTSS1 (Santa Cruz M7-P3A7 sc-101390), WWP1
(Santa Cruz Biotechnology N-20 sc-11892), RUNX1
(Active Motif #39000), Cdk2 (Santa Cruz Biotechnology
M2 sc-163). Secondary antibodies used were from Santa
Cruz Biotechnology and were diluted 1:5000 in 1% (w/v)
milk in PBS: donkey anti-goat IgG-HRP (sc-2020), goat
anti-mouse IgG-HRP (sc-2005), and goat anti-rabbit IgG-
HRP (sc-2004). After incubation with primary and sec-
ondary antibodies, the membranes were washed three
times for 30 min each with 0.1% (v/v) Tween-20 in PBS.
HRP reaction was achieved by one minute incubation with
Perkin Elmer Western Lightning ECL (NEL102001EA).
Membranes were exposed to Kodak BioMax Light File for
Chemiluminescent Imaging (#868-9358) in serial exposure
times to empirically determine the exposure time at which
the signal was most linear.
Matrigel invasion and migration assays
Proliferating MDA-MB-231 cells were trypsinized and
counted using Cellometer Auto T4 Cell Counter. A cell
suspension of 100,000 cells/mL in growth medium was
prepared and 100 μL of the suspension was loaded
into each BD Matrigel 24-well 8.0 μm PET Membrane
Invasion Chamber (#354483). Matrigel coated plates, and
control insert plates had 500 μL NIH3T3-conditioned
medium loaded in the bottom as the chemoattractant.
Plates and chemoattractant medium were incubated at
37 °C for 3–4 h prior to loading MDA-MB-231 cells.
Cells were incubated for 16 h at 37°C in 5% CO2 and
then fixed and stained using the Fisher HealthCare
PROTOCOL Hema 3 Manual Staining System (#22-122-
911) according to the manufacturer’s instructions. Cotton
swabs were used to eliminate cells which did not migrate/
invade as well as Matrigel. Cells were counted using an
inverted light microscope. To control for proliferation
effects, rates of cellular invasion through Matrigel were
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normalized by rates of cellular migration through control
plastic-only insert wells.
Transient transfection
Proliferating MDA-MB-231 cells were transfected with
50nM of siRNA/miRNA using Oligofectamine (Invitrogen
#12252-011) according to the Oligofectamine protocol.
siRNAs
Dharmacon SMARTpool: ON-TARGETplus RUNX2
siRNA (L-012665-00-0005); Dharmacon SMARTpool: ON-
TARGETplus NOV siRNA (L-010527-00-0005); Dharmacon
ON-TARGETplus Non-targeting Pool (D-001810-10-05).
miRNAs and anti-miRNAs
Dharmacon miRIDIAN microRNA hsa-mir-30c-1 mimic
(C-300542-03-0005); Dharmacon miRIDIAN microRNA
hsa-mir-30c-1* mimic (C-301199-01-0005); Dharmacon
miRIDIAN microRNA hsa-mir-30c-1 haripin inhibitor
(IH-300542-07-0005); Dharmacon miRIDIAN micro-
RNA Mimic Negative Control #1 (CN-001000-01-05);
Dharmacon miRIDIAN microRNA Hairpin Inhibitor
Negative Control #1 (IN-001005-01-05).
Screen for hsa-mir-30c targets
The top 300 targets of hsa-mir-30c based on mirSVR
were downloaded from www.microrna.org in January
2011. Gene symbols were used to access gene ontology
(GO) terms from DAVID (http://david.abcc.ncifcrf.gov)
and gene reference into function (GeneRIF) from NCBI
(http://www.ncbi.nlm.nih.gov/gene/about-generif ). Genes
whose GO terms or GeneRIFs were associated with
invasion, migration, extracellular matrix, or transcription
factors were selected and qPCR primers were designed.
After 48 h of transfection, RNA was isolated, cDNA was
amplified and Real Time qPCR was carried out to detect
the relative levels of mRNAs following transfection with
hsa-mir-30c.
Additional files
Additional file 1: Figure S1. Western blot screening of potential
cancer-related targets of hsa-mir-30c. (A and B) Western blots showing
protein levels of FOXG1, SATB2, SMAD2, MTSS1, WWP1, RUNX1, and CDK2
in whole cell lysates from MDA-MB-231 cells following 36 hours of
transient transfection with either mock (M), non-targeting miRNA
(NT), or hsa-mir-30c (30c).
Additional file 2: Figure S2. Alignment of mir-30 family members on
the NOV 3’-UTR. For each of the predicted sites of targeting by hsa-mir-30c
on the NOV 3’-UTR (A-C), if an alignment is possible, the alignment of each
mir-30 member is presented. Alignment of hsa-mir-30 family members (top
sequences) with the 3’-UTR of NOV (bottom sequences); the 5’-positions
within the NOV 3’-UTR are relative to the 5’-start of the 3’-UTR for each of
the three predicted targeting sites. Target scores are provided by mirSVR.
Uppercase letters linked with a “|” character indicates a perfect match, while
uppercase letters linked with a “:” indicate a wobble pair.
Abbreviations
3’-UTR: Three prime untranslated region; ADAM22: Homo sapiens ADAM
metallopeptidase domain 22; BCL: Homo sapiens B-cell lymphoma 2; BMP-2: Homo
sapiens bone morphogenetic protein 2; BUB3: Homo sapiens BUB3 mitotic
checkpoint protein; CCN: Family of extracellular matrix proteins, which includes
NOV; CELSR3: Homo sapiens cadherin EGF LAG seven-pass G-type receptor 3;
DYNLT3: Homo sapiens dynein, light chain, Tctex-type 3; EGF: Homo
sapiens epidermal growth factor; ER: Homo sapiens estrogen receptor
alpha; GO: Gene ontology; HPRT: Homo sapiens hypoxanthine-guanine
phosphoribosyltransferase; MCF-7: Poorly invasive, malignant breast
cancer cell line; MDA-MB-231: Metastatic breast cancer cell line;
NEDD4: Homo sapiens neural precursor cell expressed, developmentally
down-regulated 4, E3 ubiquitin protein ligase; NOV/CCN3: Homo sapiens
nephroblastoma overexpressed; PTEN: Homo sapiens phosphatase and tensin
homolog; PTPN3: Homo sapiens protein tyrosine phosphatase, non-receptor
type 3; R398A: Arginine 398 mutated to alanine; RNA-seq: Ribonucleic acid
sequencing; RUNX2: Homo sapiens runt-related transcription factor 2;
Runx2: Mus musculus runt-related transcription factor 2; SRC-1: Homo sapiens
V-Src avian sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog;
TBFβ1: Homo sapiens transforming growth factor, beta 1; TWF1: Homo
sapiens twinfilin actin-binding protein 1; VIM: Homo sapiens vimentin;
Y428A: Tyrosine 428 mutated to alanine; hsa-mir-30c: Homo sapiens miRNA 30c;
hsa-mir-30c-3p: Alternative, 3’-form of hsa-mir-30c; hsa-mir-30c-5p: Canonical,
5’-form of hsa-mir-30c; mRNA: Messenger ribonucleic acid; metasta-miR: An
miRNA that promotes cancer cell metastasis; miRNA: Small non-coding
ribonucleic acid; mirSVR: A score derived from a machine learning
method for ranking miRNA target sites; mmu-mir-30c: Mus musculus
miRNA 30c; onco-miR: An miRNA that has oncogenic functions; p-Smad1: Homo
sapiens SMAD family member 1, phosphorylated; p53: Homo sapiens tumor
suppressor protein 53; pre-miRNA: immature transcript of an miRNA;
qPCR: Quantitative polymerase chain reaction; siRNA: Short interfering
ribonucleic acid.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
qPCR for miRNAs performed by JRD and HT. qPCR for RUNX2 and NOV
performed and analyzed by JRD. siRNA and miRNA transfections performed
by JRD. Invasion assays performed by JRD and HT. Western blotting
performed by JRD. MDA-MB-231 cells stably overexpressing Runx2 and
Runx2-RY engineered by DH. Initial cancer-centric screens for hsa-mir-30c
targets in MDA-MB-231 cells performed by YH and JP. Ontological and
qPCR screen was designed and executed by JRD. Study was executed
under the guidance of JBL, AJVW, JLS, GSS, and JP, who contributed to
the writing of this manuscript. All authors read and approved the final
manuscript.
Acknowledgements
The authors acknowledge financial support from the National Institutes of
Health (National Cancer Institute P01 CA082834, National Institute of Dental
and Craniofacial Research R37 DE012528, National Institute of Arthritis and
Musculoskeletal and Skin Diseases R01 AR039588).
Author details
1Department of Cell and Developmental Biology, University of Massachusetts
Medical School, 55 Lake Ave, North, Worcester, MA 01655, USA. 2Current
address: Center for Computational Molecular Biology, Department of
Molecular Biology, Cell Biology, and Biochemistry, and Department of
Computer Science, Brown University, 115 Waterman Street, Providence, RI
02912, USA. 3Current address: Heisenberg-Group for Molecular Skeletal Biology,
Department of Trauma, Hand, and Reconstructive Surgery, University Medical
Center Hamburg-Eppendorf, Hamburg, Germany. 4Current address: Department
of Biochemistry and Vermont Cancer Center, University of Vermont College of
Medicine, 89 Beaumont Avenue, Burlington, VT 05405-0068, USA. 5Current
address: Departments of Orthopedic Surgery and Biochemistry & Molecular
Biology, Mayo Clinic, 200 First Street SW, Medical Sciences Building 3-69,
Rochester, MN 55905, USA. 6Current address: Department of Anatomy and
Cell Biology, Rush University Medical Center, Armour Academic Center,
600 S, Paulina Street, Suite 507, Chicago, IL 60612, USA.
Dobson et al. Cancer Cell International 2014, 14:73 Page 12 of 14
http://www.cancerci.com/content/14/1/73
Received: 19 March 2014 Accepted: 19 July 2014
Published: 2 August 2014
References
1. Talmadge JE, Fidler IJ: AACR centennial series: the biology of cancer
metastasis: historical perspective. Cancer Res 2010, 70(14):5649–5669.
2. Gupta GP, Massague J: Cancer metastasis: building a framework. Cell 2006,
127(4):679–695.
3. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation.
Cell 2011, 144(5):646–674.
4. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D,
Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D,
Foekens JA: Gene-expression profiles to predict distant metastasis of lymph-
node-negative primary breast cancer. Lancet 2005, 365(9460):671–679.
5. Ebert MS, Sharp PA: Roles for microRNAs in conferring robustness to
biological processes. Cell 2012, 149(3):515–524.
6. Croce CM: Causes and consequences of microRNA dysregulation in
cancer. Nat Rev Genet 2009, 10(10):704–714.
7. O’Day E, Lal A: MicroRNAs and their target gene networks in breast
cancer. Breast Cancer Res 2010, 12(2):201.
8. Hurst DR, Edmonds MD, Welch DR:Metastamir: the field of metastasis-regulatory
microRNA is spreading. Cancer Res 2009, 69(19):7495–7498.
9. Pencheva N, Tavazoie SF: Control of metastatic progression by microRNA
regulatory networks. Nat Cell Biol 2013, 15(6):546–554.
10. Valastyan S: Roles of microRNAs and other non-coding RNAs in breast
cancer metastasis. J Mammary Gland Biol Neoplasia 2012, 17(1):23–32.
11. Ell B, Mercatali L, Ibrahim T, Campbell N, Schwarzenbach H, Pantel K,
Amadori D, Kang Y: Tumor-induced osteoclast miRNA changes as
regulators and biomarkers of osteolytic bone metastasis. Cancer Cell
2013, 24(4):542–556.
12. The Cancer Genome Atlas Network: Comprehensive molecular portraits of
human breast tumours. Nature 2012, 490(7418):61–70.
13. Zhang Y, Xie RL, Croce CM, Stein JL, Lian JB, van Wijnen AJ, Stein GS: A
program of microRNAs controls osteogenic lineage progression by
targeting transcription factor Runx2. Proc Natl Acad Sci U S A 2011,
108(24):9863–9868.
14. Pratap J, Lian JB, Stein GS: Metastatic bone disease: role of transcription
factors and future targets. Bone 2011, 48(1):30–36.
15. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A,
Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C,
Schultz N: The cBio cancer genomics portal: an open platform for exploring
multidimensional cancer genomics data. Canc Discov 2012, 2(5):401–404.
16. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y,
Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N: Integrative
analysis of complex cancer genomics and clinical profiles using the
cBioPortal. Sci Signal 2013, 6(269):l1.
17. Morini M, Mottolese M, Ferrari N, Ghiorzo F, Buglioni S, Mortarini R, Noonan DM,
Natali PG, Albini A: The alpha 3 beta 1 integrin is associated with mammary
carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity.
Int J Cancer 2000, 87(3):336–342.
18. Kim VN: MicroRNA biogenesis: coordinated cropping and dicing.
Nat Rev Mol Cell Biol 2005, 6(5):376–385.
19. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ:
miRBase: microRNA sequences, targets and gene nomenclature.
Nucleic Acids Res 2006, 34(Database issue):D140–D144.
20. Kuchenbauer F, Mah SM, Heuser M, McPherson A, Ruschmann J, Rouhi A,
Berg T, Bullinger L, Argiropoulos B, Morin RD, Lai D, Starczynowski DT,
Karsan A, Eaves CJ, Watahiki A, Wang Y, Aparicio SA, Ganser A, Krauter J,
Döhner H, Döhner K, Marra MA, Camargo FD, Palmqvist L, Buske C,
Humphries RK: Comprehensive analysis of mammalian miRNA* species
and their role in myeloid cells. Blood 2011, 118(12):3350–3358.
21. Betel D, Wilson M, Gabow A, Marks DS, Sander C: The microRNA.org
resource: targets and expression. Nucleic Acids Res 2008,
36(Database issue):D149–D153.
22. Pruitt KD, Tatusova T, Klimke W, Maglott DR: NCBI Reference Sequences:
current status, policy and new initiatives. Nucleic Acids Res 2009,
37(Database issue):D32–D36.
23. da Huang W, Sherman BT, Lempicki RA: Systematic and integrative
analysis of large gene lists using DAVID bioinformatics resources.
Nat Protoc 2009, 4(1):44–57.
24. Bohlig L, Metzger R, Rother K, Till H, Engeland K: The CCN3 gene coding
for an extracellular adhesion-related protein is transcriptionally activated
by the p53 tumor suppressor. Cell Cycle 2008, 7(9):1254–1261.
25. Doghman M, Arhatte M, Thibout H, Rodrigues G, De Moura J, Grosso S,
West AN, Laurent M, Mas JC, Bongain A, Zambetti GP, Figueiredo BC, Auberger P,
Martinerie C, Lalli E: Nephroblastoma overexpressed/cysteine-rich protein 61/
connective tissue growth factor/nephroblastoma overexpressed gene-3
(NOV/CCN3), a selective adrenocortical cell proapoptotic factor, is
down-regulated in childhood adrenocortical tumors. J Clin Endocrinol
Metab 2007, 92(8):3253–3260.
26. Fukunaga-Kalabis M, Martinez G, Telson SM, Liu ZJ, Balint K, Juhasz I, Elder
DE, Perbal B, Herlyn M: Downregulation of CCN3 expression as a potential
mechanism for melanoma progression. Oncogene 2008, 27(18):2552–2560.
27. Ouellet V, Tiedemann K, Mourskaia A, Fong JE, Tran-Thanh D, Amir E,
Clemons M, Perbal B, Komarova SV, Siegel PM: CCN3 impairs osteoblast
and stimulates osteoclast differentiation to favor breast cancer metastasis
to bone. Am J Pathol 2011, 178(5):2377–2388.
28. Sin WC, Tse M, Planque N, Perbal B, Lampe PD, Naus CC: Matricellular
protein CCN3 (NOV) regulates actin cytoskeleton reorganization.
J Biol Chem 2009, 284(43):29935–29944.
29. Wu Q, Maniatis T: A striking organization of a large family of human
neural cadherin-like cell adhesion genes. Cell 1999, 97(6):779–790.
30. Gaziel-Sovran A, Segura MF, Di Micco R, Collins MK, Hanniford D, de Vega-Saenz
Miera E, Rakus JF, Dankert JF, Shang S, Kerbel RS, Bhardwaj N, Shao Y, Darvishian F,
Zavadil J, Erlebacher A, Mahal LK, Osman I, Hernando E:miR-30b/30d regulation
of GalNAc transferases enhances invasion and immunosuppression during
metastasis. Cancer Cell 2011, 20(1):104–118.
31. Palmgren S, Vartiainen M, Lappalainen P: Twinfilin, a molecular mailman
for actin monomers. J Cell Sci 2002, 115(Pt 5):881–886.
32. Helfer E, Nevalainen EM, Naumanen P, Romero S, Didry D, Pantaloni D,
Lappalainen P, Carlier MF: Mammalian twinfilin sequesters ADP-G-actin
and caps filament barbed ends: implications in motility. EMBO J 2006,
25(6):1184–1195.
33. Lo KW, Kogoy JM, Pfister KK: The DYNLT3 light chain directly links
cytoplasmic dynein to a spindle checkpoint protein, Bub3. J Biol Chem
2007, 282(15):11205–11212.
34. Yeh TY, Chuang JZ, Sung CH: Dynein light chain rp3 acts as a nuclear
matrix-associated transcriptional modulator in a dynein-independent
pathway. J Cell Sci 2005, 118(Pt 15):3431–3443.
35. Kim BG, Lee JH, Yasuda J, Ryoo HM, Cho JY: Phospho-Smad1 modulation
by nedd4 E3 ligase in BMP/TGF-beta signaling. J Bone Miner Res 2011,
26(7):1411–1424.
36. Amodio N, Scrima M, Palaia L, Salman AN, Quintiero A, Franco R, Botti G,
Pirozzi P, Rocco G, De Rosa N, Viglietto G: Oncogenic role of the E3
ubiquitin ligase NEDD4-1, a PTEN negative regulator, in non-small-cell
lung carcinomas. Am J Pathol 2010, 177(5):2622–2634.
37. Chung S, Nakashima M, Zembutsu H, Nakamura Y: Possible involvement of
NEDD4 in keloid formation; its critical role in fibroblast proliferation and
collagen production. Proc Jpn Acad Ser B Phys Biol Sci 2011, 87(8):563–573.
38. Mansbridge JN, Knuchel R, Knapp AM, Sutherland RM: Importance of
tyrosine phosphatases in the effects of cell-cell contact and microenvi-
ronments on EGF-stimulated tyrosine phosphorylation. J Cell Physiol 1992,
151(3):433–442.
39. Retta SF, Barry ST, Critchley DR, Defilippi P, Silengo L, Tarone G: Focal
adhesion and stress fiber formation is regulated by tyrosine
phosphatase activity. Exp Cell Res 1996, 229(2):307–317.
40. Soler C, Rousselle P, Damour O: Cadherin mediated cell-cell adhesion
is regulated by tyrosine phosphatases in human keratinocytes.
Cell Adhes Commun 1998, 5(1):13–25.
41. Brennan H, Smith S, Stoker A: Phosphotyrosine signalling as a regulator of neural
crest cell adhesion and motility. Cell Motil Cytoskeleton 1999, 42(2):101–113.
42. Pilecka I, Patrignani C, Pescini R, Curchod ML, Perrin D, Xue Y, Yasenchak J,
Clark A, Magnone MC, Zaratin P, Valenzuela D, Rommel C, Hooft van Huijsduijnen R:
Protein-tyrosine phosphatase H1 controls growth hormone receptor signaling
and systemic growth. J Biol Chem 2007, 282(48):35405–35415.
43. Zhi HY, Hou SW, Li RS, Basir Z, Xiang Q, Szabo A, Chen G: PTPH1
cooperates with vitamin D receptor to stimulate breast cancer growth
through their mutual stabilization. Oncogene 2011, 30(14):1706–1715.
44. Sagane K, Ohya Y, Hasegawa Y, Tanaka I: Metalloproteinase-like, disintegrin-like,
cysteine-rich proteins MDC2 and MDC3: novel human cellular disintegrins
highly expressed in the brain. Biochem J 1998, 334(Pt 1):93–98.
Dobson et al. Cancer Cell International 2014, 14:73 Page 13 of 14
http://www.cancerci.com/content/14/1/73
45. Zhu P, Sang Y, Xu H, Zhao J, Xu R, Sun Y, Xu T, Wang X, Chen L, Feng H, Li C,
Zhao S: ADAM22 plays an important role in cell adhesion and
spreading with the assistance of 14-3-3. Biochem Biophys Res Commun
2005, 331(4):938–946.
46. McCartan D, Bolger JC, Fagan A, Byrne C, Hao Y, Qin L, McIlroy M, Xu J, Hill AD,
Gaora PO, Young LS: Global characterization of the SRC-1 transcriptome
identifies ADAM22 as an ER-independent mediator of endocrine-resistant
breast cancer. Cancer Res 2012, 72(1):220–229.
47. Tzeng HE, Chen JC, Tsai CH, Kuo CC, Hsu HC, Hwang WL, Fong YC, Tang CH:
CCN3 increases cell motility and MMP-13 expression in human
chondrosarcoma through integrin-dependent pathway. J Cell Physiol
2011, 226(12):3181–3189.
48. Tan TW, Huang YL, Chang JT, Lin JJ, Fong YC, Kuo CC, Tsai CH, Chen YJ, Hsu HC,
Cho DY, Chen YH, Tang CH: CCN3 increases BMP-4 expression and bone
mineralization in osteoblasts. J Cell Physiol 2012, 227(6):2531–2541.
49. Ghayad SE, Vendrell JA, Bieche I, Spyratos F, Dumontet C, Treilleux I,
Lidereau R, Cohen PA: Identification of TACC1, NOV, and PTTG1 as new
candidate genes associated with endocrine therapy resistance in breast
cancer. J Mol Endocrinol 2009, 42(2):87–103.
50. Jiang WG, Watkins G, Fodstad O, Douglas-Jones A, Mokbel K, Mansel RE:
Differential expression of the CCN family members Cyr61, CTGF
and Nov in human breast cancer. Endocrine-Related Cancer 2004,
11(4):781–791.
51. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R,
Nolan T, Pfaffl MW, Shipley GL, Vandesompele J, Wittwer CT: The MIQE
guidelines: minimum information for publication of quantitative real-time
PCR experiments. Clin Chem 2009, 55(4):611–622.
52. Betel D, Koppal A, Agius P, Sander C, Leslie C: Comprehensive modeling of
microRNA targets predicts functional non-conserved and non-canonical
sites. Genome Biol 2010, 11(8):R90.
53. Pratap J, Wixted JJ, Gaur T, Zaidi SK, Dobson J, Gokul KD, Hussain S, van
Wijnen AJ, Stein JL, Stein GS, Lian JB: Runx2 transcriptional activation of
Indian Hedgehog and a downstream bone metastatic pathway in breast
cancer cells. Cancer Res 2008, 68(19):7795–7802.
54. Javed A, Barnes GL, Pratap J, Antkowiak T, Gerstenfeld LC, van Wijnen AJ,
Stein JL, Lian JB, Stein GS: Impaired intranuclear trafficking of Runx2
(AML3/CBFA1) transcription factors in breast cancer cells inhibits
osteolysis in vivo. Proc Natl Acad Sci U S A 2005, 102(5):1454–1459.
55. Barnes GL, Hebert KE, Kamal M, Javed A, Einhorn TA, Lian JB, Stein GS,
Gerstenfeld LC: Fidelity of Runx2 activity in breast cancer cells is required
for the generation of metastases-associated osteolytic disease. Cancer Res
2004, 64(13):4506–4513.
56. Pande S, Browne G, Padmanabhan S, Zaidi SK, Lian JB, van Wijnen AJ, Stein JL,
Stein GS: Oncogenic cooperation between PI3K/Akt signaling and
transcription factor Runx2 promotes the invasive properties of metastatic
breast cancer cells. J Cell Physiol 2013, 228(8):1784–1792.
57. Ouzounova M, Vuong T, Ancey PB, Ferrand M, Durand G, Le-Calvez Kelm F,
Croce C, Matar C, Herceg Z, Hernandez-Vargas H: MicroRNA miR-30 family
regulates non-attachment growth of breast cancer cells. BMC Genomics
2013, 14:139.
58. Rodriguez-Gonzalez FG, Sieuwerts AM, Smid M, Look MP, Meijer-van
Gelder ME, de Weerd V, Sleijfer S, Martens JW, Foekens JA: MicroRNA-30c
expression level is an independent predictor of clinical benefit of endocrine
therapy in advanced estrogen receptor positive breast cancer. Breast Cancer
Res Treat 2011, 127(1):43–51.
59. Cheng CW, Wang HW, Chang CW, Chu HW, Chen CY, Yu JC, Chao JI,
Liu HF, Ding SL, Shen CY: MicroRNA-30a inhibits cell migration and
invasion by downregulating vimentin expression and is a potential
prognostic marker in breast cancer. Breast Cancer Res Treat 2012,
134(3):1081–1093.
60. Mathew LK, Lee SS, Skuli N, Rao S, Keith B, Nathanson KL, Lal P, Simon MC:
Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell
renal cell carcinomas enhances HIF2alpha activity. Cancer Discovery
2014, 4(1):53–60.
61. Ling XH, Han ZD, Xia D, He HC, Jiang FN, Lin ZY, Fu X, Deng YH, Dai QS, Cai C,
Chen JH, Liang YX, Zhong WD, Wu CL: MicroRNA-30c serves as an
independent biochemical recurrence predictor and potential tumor
suppressor for prostate cancer. Mol Biol Rep 2014, 41(5):2779–2788.
62. Kong X, Xu X, Yan Y, Guo F, Li J, Hu Y, Zhou H, Xun Q: Estrogen regulates
the tumour suppressor MiRNA-30c and its target gene, MTA-1, in
endometrial cancer. PLoS One 2014, 9(3):e90810.
63. Li J, Donath S, Li Y, Qin D, Prabhakar BS, Li P: miR-30 regulates
mitochondrial fission through targeting p53 and the dynamin-related
protein-1 pathway. PLoS Genet 2010, 6(1):e1000795.
64. Jia W, Eneh JO, Ratnaparkhe S, Altman MK, Murph MM: MicroRNA-30c-2*
expressed in ovarian cancer cells suppresses growth factor-induced cellular
proliferation and downregulates the oncogene BCL9. Mol Cancer Res 2011,
9(12):1732–1745.
65. Brinkley BR, Beall PT, Wible LJ, Mace ML, Turner DS, Cailleau RM: Variations
in cell form and cytoskeleton in human breast carcinoma cells in vitro.
Cancer Res 1980, 40(9):3118–3129.
66. Riaz M, van Jaarsveld MT, Hollestelle A, der Prager-van Smissen WJ, Heine
AA, Boersma AW, Liu J, Helmijr J, Ozturk B, Smid M, Wiemer EA, Foekens JA,
Martens JW: miRNA expression profiling of 51 human breast cancer cell
lines reveals subtype and driver mutation-specific miRNAs. Breast Cancer Res
2013, 15(2):R33.
67. Volinia S, Croce CM: Prognostic microRNA/mRNA signature from the
integrated analysis of patients with invasive breast cancer. Proc Natl Acad
Sci U S A 2013, 110(18):7413–7417.
68. Enerly E, Steinfeld I, Kleivi K, Leivonen SK, Aure MR, Russnes HG, Ronneberg
JA, Johnsen H, Navon R, Rodland E, Mäkelä R, Naume B, Perälä M,
Kallioniemi O, Kristensen VN, Yakhini Z, Børresen-Dale AL: miRNA-mRNA
integrated analysis reveals roles for miRNAs in primary breast tumors.
PLoS One 2011, 6(2):e16915.
69. Farazi TA, Horlings HM, Ten Hoeve JJ, Mihailovic A, Halfwerk H, Morozov P,
Brown M, Hafner M, Reyal F, van Kouwenhove M, Kreike B, Sie D, Hovestadt
V, Wessels LF, van de Vijver MJ, Tuschl T: MicroRNA sequence and
expression analysis in breast tumors by deep sequencing. Cancer Res
2011, 71(13):4443–4453.
70. Foekens JA, Sieuwerts AM, Smid M, Look MP, de Weerd V, Boersma AW,
Klijn JG, Wiemer EA, Martens JW: Four miRNAs associated with
aggressiveness of lymph node-negative, estrogen receptor-positive human
breast cancer. Proc Natl Acad Sci U S A 2008, 105(35):13021–13026.
71. Brigstock DR: The CCN family: a new stimulus package. J Endocrinol 2003,
178(2):169–175.
72. Vallacchi V, Daniotti M, Ratti F, Di Stasi D, Deho P, De Filippo A, Tragni G,
Balsari A, Carbone A, Rivoltini L, Parmiani G, Lazar N, Perbal B, Rodolfo M:
CCN3/nephroblastoma overexpressed matricellular protein regulates
integrin expression, adhesion, and dissemination in melanoma. Cancer Res
2008, 68(3):715–723.
73. Benini S, Perbal B, Zambelli D, Colombo MP, Manara MC, Serra M, Parenza M,
Martinez V, Picci P, Scotlandi K: In Ewing’s sarcoma CCN3(NOV) inhibits
proliferation while promoting migration and invasion of the same cell type.
Oncogene 2005, 24(27):4349–4361.
74. Manara MC, Perbal B, Benini S, Strammiello R, Cerisano V, Perdichizzi S, Serra M,
Astolfi A, Bertoni F, Alami J, Yeger H, Picci P, Scotlandi K: The expression of ccn3
(nov) gene in musculoskeletal tumors. Am J Pathol 2002, 160(3):849–859.
75. Sin WC, Bechberger JF, Rushlow WJ, Naus CC: Dose-dependent differential
upregulation of CCN1/Cyr61 and CCN3/NOV by the gap junction protein
Connexin43 in glioma cells. J Cell Biochem 2008, 103(6):1772–1782.
76. Fu CT, Bechberger JF, Ozog MA, Perbal B, Naus CC: CCN3 (NOV) interacts with
connexin43 in C6 glioma cells: possible mechanism of connexin-mediated
growth suppression. J Biol Chem 2004, 279(35):36943–36950.
77. Zhang Y, Wang C: Nephroblastoma overexpressed (NOV/CCN3) gene: a
paired-domain-specific PAX3-FKHR transcription target that promotes
survival and motility in alveolar rhabdomyosarcoma cells. Oncogene 2011,
30(32):3549–3562.
doi:10.1186/s12935-014-0073-0
Cite this article as: Dobson et al.: hsa-mir-30c promotes the invasive
phenotype of metastatic breast cancer cells by targeting NOV/CCN3.
Cancer Cell International 2014 14:73.
Dobson et al. Cancer Cell International 2014, 14:73 Page 14 of 14
http://www.cancerci.com/content/14/1/73
